Generation of iPSC lines from CPVT patient carrying heterozygous mutation p.A2254V in the ryanodine receptor 2 gene.

Wener Li, Sarah Henze, Xiaojing Luo, Ying Ulbricht, Anja Richter, Nataliya Di Donato, Arthur A M Wilde, Kaomei Guan

Journal: Stem cell research 2021;53():102259

PMID: 33640691

Abstract

Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a severe inheritable cardiac disorder, which is characterized by life-threatening cardiac arrhythmias, syncope, seizures, or sudden cardiac death in response to physical exercise or emotional stress. This inherited disease is predominantly caused by mutations in the ryanodine receptor type 2 (RYR2). To minimize the cell line variations for disease modeling, we generated two induced pluripotency stem cell lines (hiPSCs: isCPVT1-2 and isCPVT1-3) from skin fibroblasts of one CPVT patient carrying the p.A2254V mutation using CytoTune2.0 Sendai virus cocktail for non-integration reprogramming. All generated iPSCs maintained pluripotency, normal karyotype, and spontaneous in vivo and in vitro differentiation capacity.

Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.

Address: Institute of Pharmacology and Toxicology, Technische Universität Dresden, Germany.; Clinic for Cardiology and Pneumology, Universitätsmedizin Göttingen, Germany.; Institute of Clinical Genetics, Technische Universität Dresden, Germany.; Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Heart Center, Amsterdam, the Netherlands.; Institute of Pharmacology and Toxicology, Technische Universität Dresden, Germany; Clinic for Cardiology and Pneumology, Universitätsmedizin Göttingen, Germany. Electronic address: [email protected].

Link outs

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.